EGFR-activating mutations, DNA copy number abundance of ErbB family, and prognosis in lung adenocarcinoma | Zendy

HsuanYu Chen | Zendy; Chia-Hsin Liu | Zendy; YaHsuan Chang | Zendy; SungLiang Yu | Zendy; BingChing Ho | Zendy; ChungPing Hsu | Zendy; TsungYing Yang | Zendy; KunChieh Chen | Zendy; Kuo-Hsuan Hsu | Zendy; JengSen Tseng | Zendy; JiunYi Hsia | Zendy; Cheng-Yen Chuang | Zendy; Chi-Sheng Chang | Zendy; Yucheng Li | Zendy; Ker-Chau Li | Zendy; GeeChen Chang | Zendy; PanChyr Yang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

EGFR-activating mutations, DNA copy number abundance of ErbB family, and prognosis in lung adenocarcinoma

Author(s) -

HsuanYu Chen,

Chia-Hsin Liu,

YaHsuan Chang,

SungLiang Yu,

BingChing Ho,

ChungPing Hsu,

TsungYing Yang,

KunChieh Chen,

Kuo-Hsuan Hsu,

JengSen Tseng,

JiunYi Hsia,

Cheng-Yen Chuang,

Chi-Sheng Chang,

Yucheng Li,

Ker-Chau Li,

GeeChen Chang,

PanChyr Yang

Publication year - 2016

Publication title -

oncotarget

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.373

H-Index - 127

ISSN - 1949-2553

DOI - 10.18632/oncotarget.7029

Subject(s) - erbb4 , adenocarcinoma , erbb , epidermal growth factor receptor , cancer research , copy number variation , mutation , erbb3 , lung , medicine , biology , oncology , gene , cancer , genetics , receptor , genome , receptor tyrosine kinase

In this study, EGFR-activating mutation status and DNA copy number abundances of members of ErbB family were measured in 261 lung adenocarcinomas. The associations between DNA copy number abundances of ErbB family, EGFR-activating mutation status, and prognosis were explored. Results showed that DNA copy number abundances of EGFR, ERBB2, ERBB3, and ERBB4 had associations with overall survival in lung adenocarcinoma with EGFR-activating mutations. In the stratification analysis, only ERBB2 showed significant discrepancy in patients carrying wild type EGFR and other members of ErbB family in patients carrying EGFR-activating mutation. This indicated that CNAs of ErbB family had effect modifications of EGFR-activating mutation status. Findings of this study demonstrate potential molecular guidance of patient management of lung adenocarcinoma with or without EGFR-activating mutations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research